AstraZeneca Complement C3 Inhibitor Patent Application EP4326876A1
Summary
The European Patent Office published AstraZeneca patent application EP4326876A1 for compositions and methods inhibiting complement component 3 expression. The application names AstraZeneca Ireland Limited as applicant with inventors including Lasaro, Melissa and McKnight, Susan. Designated states cover all EPC contracting states including Germany, France, UK, Italy, Spain, and others.
What changed
The EPO published patent application EP4326876A1 filed by AstraZeneca Ireland Limited covering antisense oligonucleotide compositions targeting complement component 3 (C3) expression. The application classifies under C12N 15/113 (antisense therapy) and A61K 31/713 (therapeutic oligonucleotides) with protection extending to all EPC contracting states.
For parties in the pharmaceutical or biotechnology sectors, this patent publication establishes AstraZeneca's intellectual property position in complement-targeted therapeutics, potentially affecting future R&D collaboration negotiations, licensing discussions, and market entry strategies in this therapeutic space.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
Publication EP4326876A1 Kind: A1 Apr 08, 2026
Applicants
Astrazeneca Ireland Limited
Inventors
LASARO, Melissa, MCKNIGHT, Susan, Faas, DUDEK, Henryk, T., PARK, Jihye, BROWN, Bob, Dale, LAI, Chengjung, KIM, SungKwon
IPC Classifications
C12N 15/113 20100101AFI20260227BHEP A61K 31/713 20060101ALI20260227BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.